

Reminder- PAXMAN invitation to Capital Market Day

PAXMAN, the world leader in chemotherapy side effect management, is pleased to invite investors and other interested parties to a Capital Market Day on Wednesday, November 26, 2025.

During the day, representatives from the company will speak about the company's core business of scalp cooling, reimbursement in the U. S. and the merger with Dignitana. There will be a strong focus on the company's latest side effect management work related to chemotherapy-induced peripheral neuropathy (CIPN), including a product demonstration.

CEO Richard Paxman OBE and Dr. Aishwarya Bandla, Regional R&D Manager at Paxman, who has led the development of a wearable limb cryocompression device to prevent CIPN, will be presenting at the event.

The event will be held at Carnegie's premises in Stockholm, Sweden and a live webcast will be available for those who cannot attend in person.

Location: Regeringsgatan 56, 111 56 Stockholm.

Date & Time: 26 November 2025, 13:00-17:00

Agenda

12:15 - 13:00 - Lunch

13:00 - 13:15 – Introduction

13:15 – 13:45 – *Richard Paxman OBE*: regulatory pathways and go-to-market strategy for Paxman's cryocompression device to prevent CIPN

13:45 - 14:45 – *Dr. Aishwarya Bandla*: the patient burden of CIPN, cryocompression trial data, and live demonstration of the device.

(15 min Q&A and break)

15:00-15:45 – Reimbursement landscape and the IBBM business model

(15 min Q&A and break)

16:00-16:45 – The impact of the Dignitana merger, followed by Q&A

16:45–17:00 – Closing remarks: summary of the day and the future of Paxman

Registration for physical or online attendance to the Capital Market Day can be done via [this link](#).

For inquiries regarding event-related questions, kindly send an email to anna.olsson@carnegie.se.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. In 2025, PAXMAN AB acquired Dignitana, merging to form a stronger united company.

Today, PAXMAN's portfolio includes both the Paxman and DigniCap systems with several thousand installations in hospitals, clinics and treatment centres worldwide, reaffirming PAXMAN as the leading global supplier of Scalp Cooling technology.

PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden). Subsidiaries of the PAXMAN Group are Paxman Coolers Limited (Huddersfield UK), Paxman Inc. (Houston, Texas US), Paxman Canada (Toronto, Ontario CA), Dignitana AB (Lund, Sweden), Dignitana Inc. (Dallas, TX US), and Dignitana S.r.l. (Milan, IT).

The PAXMAN share is listed on Nasdaq First North Growth Market.
FNCA Sweden AB is the company's Certified Adviser.

Attachments

[Reminder- PAXMAN invitation to Capital Market Day](#)